HomeCompareCGUI vs MRK

CGUI vs MRK: Dividend Comparison 2026

CGUI yields 4.00% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $31.8K in total portfolio value
10 years
CGUI
CGUI
● Live price
4.00%
Share price
$25.28
Annual div
$1.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$516.95
Full CGUI calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — CGUI vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGUIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGUI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGUI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGUI
Annual income on $10K today (after 15% tax)
$339.92/yr
After 10yr DRIP, annual income (after tax)
$439.41/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,157.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGUI + MRK for your $10,000?

CGUI: 50%MRK: 50%
100% MRK50/50100% CGUI
Portfolio after 10yr
$41.8K
Annual income
$5,315.37/yr
Blended yield
12.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CGUI
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGUI buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGUIMRK
Forward yield4.00%2.81%
Annual dividend / share$1.01$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$25.9K$57.7K
Annual income after 10y$516.95$10,113.78
Total dividends collected$4.6K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGUI vs MRK ($10,000, DRIP)

YearCGUI PortfolioCGUI Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,100$399.90$11,213$373.04$113.00MRK
2$12,292$414.85$12,667$512.06$375.00MRK
3$13,581$429.34$14,439$708.14$858.00MRK
4$14,976$443.35$16,640$988.16$1.7KMRK
5$16,481$456.88$19,432$1,394.07$3.0KMRK
6$18,104$469.90$23,057$1,992.90$5.0KMRK
7$19,854$482.43$27,889$2,894.79$8.0KMRK
8$21,738$494.44$34,518$4,286.29$12.8KMRK
9$23,766$505.95$43,912$6,494.35$20.1KMRK
10$25,946$516.95$57,714$10,113.78$31.8KMRK

CGUI vs MRK: Complete Analysis 2026

CGUIStock

To provide current income consistent with an ultra-short duration profile, focused on preservation of capital.Distinguishing Characteristics The fund invests primarily in U.S. dollar denominated, investment-grade, short-term debt, including short-term money market instruments such as commercial paper and certificates of deposit, U.S. government bonds, corporate securities and asset-backed securities. The fund will normally invest more than 25% of its assets in securities issued by companies in the financials group of industries. The fund may invest substantially in debt securities that are tied economically to countries outside the United States, including securities issued by foreign corporations or foreign governments and their agencies and instrumentalities. The fund may also invest in futures contracts and swaps, which are types of derivatives. A derivative is a financial contract, the value of which is based on the value of an underlying financial asset (such as a stock, bond or currency), a reference rate or a market index.The fund will invest at least 80% of its assets in bonds and other debt securities that accrue income, which may be represented by derivatives. The fund consists primarily of investment-grade debt with a minimum short-term rating of P-2, A-2, F2, or a minimum long-term rating of BBB- or Baa3, in each case given by the Nationally Recognized Statistical Rating Organizations designated by the fund’s investment adviser or unrated but determined to be of equivalent quality by the fund’s investment adviser. The fund may invest up to 5% in debt securities rated BB+ or Ba1 or below, but with a minimum rating of BB- (or Ba3). The fund normally seeks to maintain an average portfolio duration of one year or less, and a dollar-weighted average maturity of two years or less. The fund will normally invest more than 25% of its assets in securities issued by companies in the financials group of industries.

Full CGUI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CGUI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGUI vs SCHDCGUI vs JEPICGUI vs OCGUI vs KOCGUI vs MAINCGUI vs JNJCGUI vs ABBVCGUI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.